GlassScriptPhysician profile
Phi A Tran
NPI 1588192736
$660.98
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.25 · 2021: $93.36 · 2022: $161 · 2023: $307 · 2024: $54.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $156.26 | 2023 | Xarelto |
| Vifor Pharma, INC. | $111.63 | 2021-2023 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $46.04 | 2022 | |
| Pfizer INC. | $45.20 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.72 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $42.89 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $36.23 | 2021-2023 | Nuzyra |
| Boston Scientific Corporation | $34.30 | 2024 | Watchman Flx |
| Inari Medical, INC. | $29.31 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $22.43 | 2023 | Recarbrio, Dificid, Zerbaxa |
| Bioxcel Therapeutics, INC. | $21.16 | 2023 | Igalmi |
| Esperion Therapeutics, INC. | $20.15 | 2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.57 | 2021 | |
| Fisher & Paykel Healthcare INC | $17.83 | 2023 | Fisher & Paykel Healthcare |
| Novartis Pharmaceuticals Corporation | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phi Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.